Novelty Nobility, a biotech specializing in antibody drug discovery, said on Monday that it launched the PREXISE-D Order-to-Discovery Solution (OTD Solution), a fully humanized mouse antibody discovery service for pharmaceutical companies in Korea.
Novelty Nobility's PREXISE-D is a fit-for-purpose antibody discovery and design platform based on repeatedly injecting specific antigens into humanized mice. It secures the variable domain sequence of a new fully humanized antibody using a human gene replacement mouse. This technique is already commonly used by global companies to discover fully human antibodies.
The company created PREXISE-D by combining the 25 years of antibody discovery expertise of its CEO Park Sang-gyu with the expertise of advanced companies and is developing multiple pipelines based on its self-developed antibodies.
The OTD Solution launched this time consists of two stages including the design and discovery of antibodies.
In the design phase, the customer defines the properties of the antibody they want to discover, suitable antigens, and the screening process according to their desired purpose, which usually takes about 3 months. The desired antibody properties are created by finding the right spot at the intersection of potentially multiple antibody sites. However, this process can be skipped if antibody properties have already been determined.
Meanwhile, the discovery phase is carried out within Novelty Novility for about six months, and upon completion of the discovery, the client will receive a variable domain sequence of at least two monoclonal antibodies, the hybridoma-derived antibody cell lines, and the antibody characterization result report.
"We have been receiving inquiries from many companies to provide antibodies to secure new pipelines so we have launched the OTD Solution to help domestic companies that wish to secure new antibodies," said Novelty Nobility CEO Park Sang-gyu. "With the OTD Solution, which reflects our philosophy that a good antibody is an antibody that is fit for purpose, we will contribute to helping domestic bio companies secure quality pipelines."
The company also added that its OTD Solution offers antibody discovery in normal mice at a comparatively affordable price and the mouse antibodies can be subsequently humanized and developed into therapeutics. However, the humanized platform offers a shorter development time as no additional target affinity maturation or humanization is required after antibody discovery, and the possibility of immunogenicity is low.